News
June 11, 2025 | COMPANY | NEWS | ONCOLOGY GALEAS™ Bladder, our urine test for the non-invasive detection and monitoring of bladder cancer, has appeared in the European Association of Urology (EAU) Guidelines on Non-Muscle-Invasive Bladder Cancer in a surveillance setting. The Guidelines are developed by the EAU as best practice clinical guidelines primarily for frontline urologists across…
Read MoreThe London Clinic is the first independent hospital to offer GALEAS™ bladder cancer tests
New collaboration with Nonacus Clinical Services enables The London Clinic to offer patients a non-invasive means to test for bladder cancer May 30, 2025 | COMPANY | NEWS | ONCOLOGY Nonacus Clinical Services, the UK laboratory delivering genomic cancer testing services to the NHS and private healthcare providers, is working with The London Clinic to help more patients…
Read MoreJuly 31, 2024 | COMPANY | NEWS | ONCOLOGY Arlene Rose is 69 and received a positive test earlier this year after joining the NHS BRCA Screening programme. This is her story. “In November 2023, my daughter-in-law sent me a WhatsApp message linking to the NHS BRCA Screening programme stating, ‘I am getting tested, are you?’ “As an Ashkenazi…
Read MoreNHS trusts evaluate GALEAS Bladder to improve bladder cancer pathway
New technologies are key to meeting new Government targets for the NHS in the UK. GALEAS Bladder is a simple urine test that could save the NHS £140 million per year alone. January 8, 2025 | COMPANY | NEWS | ONCOLOGY Owing to the current standard of care, bladder cancer is one of the most expensive cancers to treat…
Read MoreNew technologies are key to meeting new Government targets for NHS
January 8, 2025 | COMPANY | NEWS | ONCOLOGY NHS Trusts evaluate new test to improve bladder cancer pathway. Owing to the current standard of care, bladder cancer is one of the most expensive cancers to treat GALEAS Bladder is a simple urine test that could save NHS £140 million a year Results and feedback from NHS Trust evaluation…
Read MoreGALEAS™ Bladder provides pain-free way to deliver negative result
January 6, 2025 | COMPANY | NEWS | ONCOLOGY Mrs Smith is 79 and has recently received a negative result from the GALEAS™ Bladder Cancer test. Here she tells us her story. In 2016, Mrs Smith had an operation on the bottom of her spine to remove an endocrine tumour. Seven years later, during a routine blood test, the…
Read MoreGALEAS™ Bladder results create excitement at BAUS Oncology
Nov 22, 2024 | COMPANY | NEWS | ONCOLOGY More than 20 NHS Trusts now plan to join the GALEAS Bladder service evaluation Our ‘GALEAS Bladder – adoption in practice’ event took place last week, alongside the BAUS Oncology event, together generating a huge amount of excitement and interest in our NHS service evaluation of GALEAS Bladder, a non-invasive…
Read MoreUK Genomics Spotlight 2024: Celebrating success and looking ahead
November, 2024 | COMPANY | NEWS | ONCOLOGY November 2024 – Birmingham – Informed Genomics has been included in the Department for Business and Trade’s (DBT) Genomics Spotlight 2024, which showcases the UK’s expertise in genomics and latest developments that make the UK a hub for genomics business and investment. Informed Genomics was founded in 2022 and some of…
Read MoreIncreased investment in NHS is welcome, UK Budget 2024
November 1, 2024 | COMPANY | NEWS | ONCOLOGY Jeff Bousfield, CEO of Advanced Genomics, welcomes the increased NHS funding announced in the UK Government’s Budget yesterday, which can further accelerate technology adoption from innovative UK companies to reduce costs and cut waiting lists in our health system. Jeff commented: “For the majority in the UK, our NHS is…
Read MoreNonacus introduces its first ultrasensitive qPCR assay for ESR1 mutation detection
Nonacus Ltd, has launched GALEAS uPCR ESR1, an ultrasensitive qPCR (uPCR) assay developed to detect eleven mutations in the ESR1 gene which are known to be associated with resistance to endocrine therapy October 31, 2024 | COMPANY | NEWS | ONCOLOGY Endocrine therapy is the main therapeutic option for estrogen receptor-positive (ER+), HER2 negative (HER2-) breast cancers, which account…
Read More